Suppr超能文献

慢性肠系膜缺血血管内再通治疗的中期结果。

Mid-term outcome of endovascular revascularization for chronic mesenteric ischaemia.

机构信息

Vascular Centre Malmö-Lund, Malmö University Hospital, Malmö, Sweden.

出版信息

Br J Surg. 2010 Feb;97(2):195-201. doi: 10.1002/bjs.6819.

Abstract

BACKGROUND

: This study aimed to assess mid-term outcome after endovascular revascularization of chronic occlusive mesenteric ischaemia (CMI) and to identify possible predictors of mortality.

METHODS

: Consecutive patients undergoing primary elective stenting for CMI between 1995 and 2007 were registered prospectively in a database. Patients with acute ischaemia were excluded. Retrospective case-note review and data analysis were performed.

RESULTS

: Forty-three patients (10 men) were treated for stable (n = 30) or exacerbated (n = 13) CMI. Their median (interquartile range (i.q.r.)) age was 70 (60-79) years. Revascularization was successful in 47 of 49 vessels. The superior mesenteric artery (SMA), either alone (n = 34) or in combination with the coeliac trunk (n = 6), was the predominant target vessel. No patient died within 30 days. Median follow-up was 43 (i.q.r. 25-63) months and the estimated (s.e.) 3-year overall survival rate was 76(7) per cent. Two patients died from distal SMA occlusive disease and intestinal infarction after 6 and 18 months respectively. Previous stroke (P = 0.016), male sex (P = 0.057) and age (P = 0.066) were associated with mid-term mortality on univariable, but not multivariable analysis. Reintervention was needed in 14 patients, achieving a 3-year cumulative rate of freedom from recurrent symptoms of 88(5) per cent.

CONCLUSION

: Endovascular treatment provided high early and mid-term survival rates in this series of patients with CMI, with low complication rates.

摘要

背景

本研究旨在评估慢性闭塞性肠系膜缺血(CMI)血管内再通治疗的中期结果,并确定可能的死亡率预测因素。

方法

1995 年至 2007 年间连续对接受原发性选择性支架置入术治疗 CMI 的患者进行前瞻性登记,排除急性缺血患者。回顾性病历复查和数据分析。

结果

43 例患者(10 例男性)因稳定(n=30)或加重(n=13)CMI 接受治疗。他们的中位(四分位间距(IQR))年龄为 70(60-79)岁。49 支血管中有 47 支再通成功。肠系膜上动脉(SMA)是主要的靶血管,单独(n=34)或联合腹腔干(n=6)。没有患者在 30 天内死亡。中位随访时间为 43(IQR 25-63)个月,估计(s.e.)3 年总生存率为 76(7)%。2 例患者分别在 6 个月和 18 个月后因 SMA 远端闭塞性疾病和肠梗死死亡。既往卒中(P=0.016)、男性(P=0.057)和年龄(P=0.066)在单变量分析中与中期死亡率相关,但在多变量分析中无相关性。14 例患者需要再次干预,3 年无复发生存率为 88(5)%。

结论

在本系列 CMI 患者中,血管内治疗提供了高的早期和中期生存率,并发症发生率低。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验